Cargando…

Antiviral Compounds from Myxobacteria

Viral infections including human immunodeficiency virus (HIV), cytomegalovirus (CMV), hepatitis B virus (HBV), and hepatitis C virus (HCV) pose an ongoing threat to human health due to the lack of effective therapeutic agents. The re-emergence of old viral diseases such as the recent Ebola outbreaks...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulwa, Lucky S., Stadler, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163824/
https://www.ncbi.nlm.nih.gov/pubmed/30029487
http://dx.doi.org/10.3390/microorganisms6030073
_version_ 1783359454139383808
author Mulwa, Lucky S.
Stadler, Marc
author_facet Mulwa, Lucky S.
Stadler, Marc
author_sort Mulwa, Lucky S.
collection PubMed
description Viral infections including human immunodeficiency virus (HIV), cytomegalovirus (CMV), hepatitis B virus (HBV), and hepatitis C virus (HCV) pose an ongoing threat to human health due to the lack of effective therapeutic agents. The re-emergence of old viral diseases such as the recent Ebola outbreaks in West Africa represents a global public health issue. Drug resistance and toxicity to target cells are the major challenges for the current antiviral agents. Therefore, there is a need for identifying agents with novel modes of action and improved efficacy. Viral-based illnesses are further aggravated by co-infections, such as an HIV patient co-infected with HBV or HCV. The drugs used to treat or manage HIV tend to increase the pathogenesis of HBV and HCV. Hence, novel antiviral drug candidates should ideally have broad-spectrum activity and no negative drug-drug interactions. Myxobacteria are in the focus of this review since they produce numerous structurally and functionally unique bioactive compounds, which have only recently been screened for antiviral effects. This research has already led to some interesting findings, including the discovery of several candidate compounds with broad-spectrum antiviral activity. The present review looks at myxobacteria-derived antiviral secondary metabolites.
format Online
Article
Text
id pubmed-6163824
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61638242018-10-10 Antiviral Compounds from Myxobacteria Mulwa, Lucky S. Stadler, Marc Microorganisms Review Viral infections including human immunodeficiency virus (HIV), cytomegalovirus (CMV), hepatitis B virus (HBV), and hepatitis C virus (HCV) pose an ongoing threat to human health due to the lack of effective therapeutic agents. The re-emergence of old viral diseases such as the recent Ebola outbreaks in West Africa represents a global public health issue. Drug resistance and toxicity to target cells are the major challenges for the current antiviral agents. Therefore, there is a need for identifying agents with novel modes of action and improved efficacy. Viral-based illnesses are further aggravated by co-infections, such as an HIV patient co-infected with HBV or HCV. The drugs used to treat or manage HIV tend to increase the pathogenesis of HBV and HCV. Hence, novel antiviral drug candidates should ideally have broad-spectrum activity and no negative drug-drug interactions. Myxobacteria are in the focus of this review since they produce numerous structurally and functionally unique bioactive compounds, which have only recently been screened for antiviral effects. This research has already led to some interesting findings, including the discovery of several candidate compounds with broad-spectrum antiviral activity. The present review looks at myxobacteria-derived antiviral secondary metabolites. MDPI 2018-07-19 /pmc/articles/PMC6163824/ /pubmed/30029487 http://dx.doi.org/10.3390/microorganisms6030073 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mulwa, Lucky S.
Stadler, Marc
Antiviral Compounds from Myxobacteria
title Antiviral Compounds from Myxobacteria
title_full Antiviral Compounds from Myxobacteria
title_fullStr Antiviral Compounds from Myxobacteria
title_full_unstemmed Antiviral Compounds from Myxobacteria
title_short Antiviral Compounds from Myxobacteria
title_sort antiviral compounds from myxobacteria
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163824/
https://www.ncbi.nlm.nih.gov/pubmed/30029487
http://dx.doi.org/10.3390/microorganisms6030073
work_keys_str_mv AT mulwaluckys antiviralcompoundsfrommyxobacteria
AT stadlermarc antiviralcompoundsfrommyxobacteria